Acetyl tetrapeptide-XV dicitur a endomorphin-2 per an * acetylation modificatione suo N-terminatio tyrosine residuum. Haec specifica chemica modificatio communiter adhibetur ut vel augeat stabilitatem peptidis vel actionem biologicam mutaverit.
Endomorphin-2 ipsa est agonista bene documentata endogenosa cum summa affinitate et delectu ad the μ-receptores opioidei (MOR) sicut habet rationem definiendi. Due to its structural similarity to this parent compound, Acetyl Tetrapeptide-15 praesumitur possidere functiones biologicas fere identificas.
Primarius, et prope diem exclusive, applicatio huius peptidis acetylatae in fucis incidit industriam – sensitive skin products being the most prevalent example of its use as an active ingredient.
Sequentia
Ac-Tyr-Pro-Phe-Phe-NH2
CAS Number
928007-64-1
Formulae hypotheticae
C34H39N5O6
M. Pondus
613.70 g / mol
Investigatio de Acetyl Tetrapeptide-15
The development of acetyl tetrapeptide-15 aims to elevate the excitation threshold of μ-opioid receptor-expressing neurons; endorphin-sicut meatus usus. Enhancing skin tolerance to various external stimuli and reducing inflammatory, chronic and even neuropathic pain related to skin hyperreactivity is the desired end result.
1.Modulans CGRP Release
CGRP (calcitonin gene-relatas peptide) est potens pro inflammatione neuropeptide. Sensorium neurons dimittere eam, vasodilation and subsequent redness/edema being two direct manifestations of this sensitivity. Skin sensitivity and associated inflammatory responses are at least partially mediated by CGRP.
Activatio TRPV1 receptoris (capsaicin, calor, depolarizing agentibus omnia serve ut triggers) ducit ad remissionis. Co-cultus sensoria neurona cum acetylo tetrapeptido tractata insignem inhibitionem utriusque capsaicini et 15 praebuit. Potassium chloridum (KCl, aut kalium sal) adductus CGRP release – ad effectum comparandum, aut melius, notum TRPV1 adversario capsazepine.
2.Activatio μ-Receptores Opioideae
In vitro primordium: Intra capsaicin excitanda exemplum, acetyl tetrapeptide-15 certatim tenetur cum receptoribus µ-opioidibus in sensoriis excultis neurons. Opioides adversario naloxone adhibitus est ad confirmandam hanc obligationem.
Capsaicin ipsum ligat receptores ad TRPV1, calcium influxum CT; subsequens CGRP emissio et dolor significationis sequitur ut effectus. acetyl tetrapeptide-XV signanter reducitur hoc capsaicin-stimulatus CGRP emissio, interclusio effectus naloxone praebens necessariam confirmationem receptoris involvement.
Hos μ-receptores activum permittit acetyl tetrapeptidum 15 ut negative modulare sensuale cell activitatem; pro inflammatione neuropeptides (CGRP primum exemplum) quae sic minus dimisit. Blocking neurogenic inflammation at its source is an anti-inflammatory end-effect, deliniens esse aliud.
3.Fusce Study
Solus clinicus caecus facultatem acetyl tetrapeptidi aestimandam 15 ad minuendam cutem sensus. Augendae solutionis capsaicin concentrationes applicatae sunt nasolabialis ovile (molestiae limine esse mensura interest), cum contralateral maxillam servientes ut lorem imperium.
Repetita applicationes peptide, at 0.0015%, bis quotidie quatriduum, sequitur adhuc capsaicin challenges, showed a clear and measurable increase in that threshold.
Currently the applications of acetyl tetrapeptide-15 are still largely confined to cosmetic formulations. Core anti-sensitionis est id quod praebet; sensitivo cutis products (ad date certe) hanc rationem.
Ardens et aculeatum reducuntur, et ad punctum, all forms of discomfort or near-normalization of skin sensitivity can be achieved. New topical analgesics andor anti-inflammatory agents are a logical next step, and acetyl tetrapeptide-15 has potential in future dermatological or cosmetic science.
COA
HPLC
MS
